ArticleAnnals of hematology2025
Clinical characteristics and prognosis of EBV-Positive mature B-Cell lymphoma in children: a retrospective study.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal vasculitis as a presenting sign of Epstein-Barr virus positive diffuse large B-cell lymphoma: a case report.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epstein-Barr virus (EBV)-associated pediatric mature B-cell lymphoma is characterized by rapid progression, a poor prognosis, and a high relapse rate. However, research on this condition remains limited. This retrospective study analyzed its clinical features and prognostic factors in children. Kaplan‒Meier analysis was performed to assess the impact of tumor EBV-encoded RNA (EBER)impact status on survival, and LASSO Cox regression was used to identify risk factors. The predictive performance of a model including the identified risk factors was assessed using calibration curves and receiver operating characteristic (ROC) curves. Tumor EBER status was significantly positively correlated with the EBV-DNA level (P < 0.05). EBER-positive pediatric patients presented elevated IgA levels, reduced IgG/IgM levels, decreased CD4 + T-cell counts, and increased CD8 + T-cell counts (P < 0.05). Compared with EBER-negative patients, EBER-positive patients had worse 5-year cumulative progression-free survival (PFS) (73.33%) and cumulative overall survival (OS) (78.30%) (P < 0.05). LASSO Cox regression analysis identified EBER (PFS HR 3.48, 95% CI 1.16-10.47, P = 0.027; OS HR 8.10, 95% CI 1.80-36.38, P = 0.006) and LDH (PFS HR 3.05, 95% CI 1.07-8.68, P = 0.037; OS HR 7.38, 95% CI 1.42-38.47, P = 0.018) as key prognostic markers. The model predicted 3-/5-year survival with high accuracy, with a C-index of 0.699 (95% CI: 0.558-0.841) for PFS and AUC (95% CI) values of 0.730 (0.575-0.886) and 0.691 (0.515-0.868). For OS, the C-index was 0.810 (95% CI: 0.669-0.952), and the AUC (95% CI) values were 0.805 (0.605-1.005) and 0.817 (0.618-1.015). Pediatric patients with EBV-associated mature B-cell lymphoma present distinct clinical and prognostic features that significantly influence the tumor immune microenvironment. The risk prognostic model based on tumor EBER status and LDH level reliably predicts outcomes in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.